# US 2024/0076632 A1 · Recombinant influenza viruses with stabilized ha for replication in eggs

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2024/0076632 A1
- Document ID: US20240076632A1
- Status: Published application
- Kind: A1
- Application number: 18/461,321
- Filed: 2023-09-05
- Published: 2024-03-07
- Earliest claimed: 2019-08-27
- Assignees: The University of Tokyo; Wisconsin Alumni Research Foundation (WARF)
- Applicants: The University of Tokyo; Wisconsin Alumni Research Foundation (WARF)
- Inventors: Yoshihiro Kawaoka; Shinya Yamada; Shiho Chiba
- Web page: https://patentgrep.com/patent/US20240076632A1

## CPC

- C07K 14/005: from viruses
- C12N 7/00: Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof (preparing medicinal viral antigen or antibody compositions, e.g. virus vaccines, A61K39/00)
- A61K 39/00: Medicinal preparations containing antigens or antibodies (materials for immunoassay G01N33/53)
- A61K 39/12: Viral antigens
- A61P 31/16: for influenza or rhinoviruses
- C12N 2760/16021: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2760/16022: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16034: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16051: Methods of production or purification of viral material
- C12N 2760/16121: Viruses as such, e.g. new isolates, mutants or their genomic sequences
- C12N 2760/16122: New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C12N 2760/16134: Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C12N 2760/16151: Methods of production or purification of viral material
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)
- C12N: MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA (microbiological testing media C12Q1/00)
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

Modified influenza virus neuraminidases are described herein that improve viral replication, thus improving the yield of vaccine viruses. Expression of such modified neuraminidases by influenza virus may also stabilize co-expressed hemagglutinins so that the hemagglutinins do not undergo mutation or decrease the need for HA binding to cells.

## Claims

### Claim 1

A method to decrease influenza HA binding to cells, comprising: altering one or more residues in the HA binding pocket of HA that binds to sialic acid on allantoic membranes.

### Claim 2 (depends on 1)

The method of claim 1 wherein the residue at position 98, 153 or 183 of the HA is altered based on the numbering of H3 HA.

### Claim 3 (depends on 1)

The method of claim 1 wherein the residue at position 98 is F, G, I, V, T, H, W, or L; the residue at position 153 is A, G, I, V, T, or L; and/or the residue at position 183 is F, A, G, I, L, V, Y, W, P, or T; or the residue at position 98 is F, H, P, or W; the residue at position 153 is A, G, I, V, or L; and/or the residue at position 183 is F, Y, W, or P.
